Home / Precision Medicine (page 3)

Precision Medicine

Identification of LZTR1 Leads to Novel Insights into RAS-Driven Diseases

Mutations in RAS proteins initiate many of the most aggressive tumors, and the search for pharmacological inhibitors of these proteins has become a priority in the battle against cancer. Michail Steklov, Francesca Baietti, and colleagues from the Anna Sablina lab (VIB-KU Leuven Center for Cancer Biology) identified LZTR1 as an …

Read More »

NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells in a Novel Cancer Memory Vaccine Immunotherapy

CULVER CITY, Calif.–(BUSINESS WIRE)–The recent successes of immunotherapy, such as checkpoint inhibition, have spawned a wave of enthusiasm for immuno-oncology. Unfortunately, only a subset of cancer patients respond to checkpoint inhibitor monotherapy, and many of these checkpoint-responsive patients will eventually relapse. In addition, cellular therapy in the form of CAR-T …

Read More »

23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic Reports

Mountain View, California – October 31, 2018 – In another first, the U.S. Food and Drug Administration (FDA) granted 23andMe de novo authorization to offer reports on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications. This is the first authorization of a direct-to-consumer report on pharmacogenetics, and came …

Read More »

Lustgarten-Funded Study in Cancer Discovery Reveals Possible New Targets for Therapeutics

WOODBURY, N.Y., Oct. 26, 2018 /PRNewswire/ — Pancreatic cancer has shown to have limited effective treatment strategies.  Researchers in the Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory (CSHL) have made a discovery that could lead to a different, more effective kind of treatment. Part of the …

Read More »

Gottlieb Makes Statement on FDA’s New Steps to Modernize Drug Development, Improve Efficiency and Promote Innovation of Targeted Therapies

The FDA continues to advance new policies, modernize our programs and advance opportunities for developing more targeted therapies. Using new technology platforms such as cell and gene therapies and small molecule drugs that target the genomic basis of disease, there are more opportunities to intervene in the underlying mechanisms that cause a …

Read More »

Myriad Announces New GeneSight Study Published in Personalized Medicine

SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that a health economic study to evaluate the financial impact of the GeneSight® combinatorial pharmacogenomic (CPGx) test on major commercial health plans was published in the journal Personalized Medicine.  The …

Read More »

Gilead and Precision BioSciences Collaborate to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

FOSTER CITY, Calif. & DURHAM, N.C.–(BUSINESS WIRE)–Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS. An estimated 257 million people are living with …

Read More »

Ferring and Celmatix Partner to Advance Care in Reproductive Medicine and Accelerate Development of Personalized Interventions

SAINT-PREX, Switzerland & NEW YORK–(BUSINESS WIRE)–Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian biology and accelerating the development of personalized interventions in reproductive medicine and women’s health. This collaboration will leverage both Ferring and Celmatix’s significant expertise in women’s reproductive health …

Read More »

Vertex and Genomics plc Collaborate to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

BOSTON & OXFORD, United Kingdom–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and …

Read More »

Novartis’ Investigational PI3K inhibitor Meets Primary Endpoint in Phase 3 Breast Cancer Trial

Basel, August 23, 2018 – Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS). SOLAR-1 is evaluating BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and men with …

Read More »